Sentiment-Signal
24,9
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
59.1
13D-Filing vorhanden
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tion 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 04.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tion 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 13.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | on 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Ap |
| 12.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | sting standards for The Nasdaq Capital Market. Item 5.02 Departure of Directors or Certain Officers; Election of Direc |
Stammdaten
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Unternehmen & Branche
| Name | TENAX THERAPEUTICS, INC. |
|---|---|
| Ticker | TENX |
| CIK | 0000034956 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 249,4 Mio. USD |
| Beta | 1,19 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -52,599,000 | -1.34 | 104,227,000 | 97,071,000 |
| 2025-09-30 | 10-Q | 0 | -15,804,000 | -0.40 | 102,810,000 | 96,211,000 |
| 2025-06-30 | 10-Q | 0 | -10,847,000 | -0.27 | 105,857,000 | 103,330,000 |
| 2025-03-31 | 10-Q | 0 | -10,408,000 | -0.28 | 112,059,000 | 109,291,000 |
| 2024-12-31 | 10-K | 0 | -17,602,000 | -1.15 | 96,686,000 | 91,993,000 |
| 2024-09-30 | 10-Q | -3,961,000 | -0.19 | 99,784,745 | 97,223,000 | |
| 2024-06-30 | 10-Q | -3,575,000 | -1.83 | 10,616,909 | 8,876,000 | |
| 2024-03-31 | 10-Q | -3,799,000 | -3.12 | 14,460,264 | 12,429,000 | |
| 2023-12-31 | 10-K | -7,711,000 | -31.04 | 11,685,000 | 8,098,000 | |
| 2023-09-30 | 10-Q | 1,971,975 | 11,888,909 | 11,286,695 | ||
| 2023-06-30 | 10-Q | -1,106,338 | 14,045,499 | 13,221,658 | ||
| 2023-03-31 | 10-Q | -1,406,760 | 15,271,574 | 14,277,713 | ||
| 2022-12-31 | 10-K | 11,047,895 | 3,404,709 | 1,493,000 | ||
| 2022-09-30 | 10-Q | 2,916,537 | 4,739,020 | 3,953,851 | ||
| 2022-06-30 | 10-Q | -2,861,021 | 8,355,483 | 6,783,802 | ||
| 2022-03-31 | 10-Q | -2,721,536 | 3,737,619 | 1,606,201 | ||
| 2021-12-31 | 10-K | -32,474,358 | 5,992,235 | 4,244,668 | ||
| 2021-09-30 | 10-Q | 3,798,648 | 8,911,594 | 7,238,643 | ||
| 2021-06-30 | 10-Q | -1,717,016 | 2,885,181 | 1,471,132 | ||
| 2021-03-31 | 10-Q | -23,748,140 | 4,560,561 | 3,095,681 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-09 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 10.22 | 25,542.00 | +187,4% | |
| 2025-12-08 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 10.10 | 25,250.50 | +185,2% | |
| 2025-12-04 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 9.20 | 22,998.00 | +168,7% | |
| 2025-12-03 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 1,500 | 9.08 | 13,617.90 | +99,9% | |
| 2025-12-02 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 1,000 | 9.01 | 9,005.90 | +66,1% | |
| 2025-11-20 | Giordano Christopher Thomas | Director, Officer, CEO | Open Market Purchase | 538 | 7.59 | 4,082.72 | +30,0% | |
| 2025-11-19 | Giordano Christopher Thomas | Director, Officer, CEO | Open Market Purchase | 455 | 7.51 | 3,416.64 | +25,1% | |
| 2025-11-18 | Giordano Christopher Thomas | Director, Officer, CEO | Open Market Purchase | 1,612 | 7.75 | 12,500.42 | +91,7% | |
| 2025-11-18 | Almenoff June Sherie | Director | Open Market Purchase | 1,900 | 7.52 | 14,279.83 | +104,8% | |
| 2025-11-18 | Almenoff June Sherie | Director | Open Market Purchase | 1,900 | 7.52 | 14,279.83 | +104,8% | |
| 2025-11-17 | MCGAULEY THOMAS | Officer, Interim CFO | Open Market Purchase | 1,000 | 7.35 | 7,350.00 | +53,9% | |
| 2025-11-17 | MCGAULEY THOMAS | Officer, Interim CFO | Open Market Purchase | 2,000 | 7.34 | 14,674.00 | +107,7% | |
| 2025-11-17 | Almenoff June Sherie | Director | Open Market Purchase | 93 | 7.15 | 664.95 | +4,9% | |
| 2025-11-17 | Almenoff June Sherie | Director | Open Market Purchase | 93 | 7.15 | 664.95 | +4,9% | |
| 2025-11-17 | MCGAULEY THOMAS | Officer, Interim CFO | Open Market Purchase | 5,000 | 7.23 | 36,140.00 | +265,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.